Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

    Supports investigator-initiated, milestone-driven clinical trials requiring enhanced oversight for up to 7 years, with mechanistic studies as applicable and one trial per application.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: National Institutes of Health

    Due Dates: February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision) | February 5, 2028 (New) | March 5, 2028 (Renewal/Resubmission/Revision) | June 5, 2028 (New) | July 5, 2028 (Renewal/Resubmission/Revision) | October 5, 2028 (New) | November 5, 2028 (Renewal/Resubmission/Revision) | February 5, 2029 (New) | March 5, 2029 (Renewal/Resubmission/Revision) | June 5, 2029 (New) | July 5, 2029 (Closing; Renewal/Resubmission/Revision)

    Funding Amounts: No budget limit; requests must reflect project needs. Most trials: up to 5 years; maximum: 7 years.

    Summary: Supports implementation-ready, investigator-initiated clinical trials requiring enhanced oversight in NIAID research areas, with mechanistic studies where applicable.

    Key Information: Only one clinical trial per application; all trial planning must be completed before submission.


    Description

    The National Institute of Allergy and Infectious Diseases (NIAID) supports milestone-driven clinical trials addressing prevention, diagnosis, treatment, and disease mechanisms in infectious, allergic, and immunologic diseases. This U01 cooperative agreement is intended for investigator-initiated trials that cannot or will not be conducted through existing NIAID-supported networks or infrastructure. Trials must be ready for implementation, with documentation demonstrating readiness.

    The program supports trial conduct, completion, analysis, and related activities, including recruitment, study products, laboratory work, monitoring, regulatory activities, and final reporting. Enhanced oversight applies to non-routine interventions, unlicensed products, licensed products used for unapproved indications, or trials requiring IND/IDE oversight. NIAID staff will have substantial scientific and programmatic involvement. A single platform trial, multiple interventions, or sequential stages within one trial are permitted.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.